

Nonalcoholic Steatohepatitis (NASH) 2017 Market Insights, Epidemiology and Forecast – 2027

WiseGuyReports.com adds “Nonalcoholic Steatohepatitis (NASH) Market 2017 Global Analysis Research Report Forecasting to 2027” reports to its database.

PUNE, INDIA, November 8, 2017 /EINPresswire.com/ -- [Nonalcoholic Steatohepatitis \(NASH\) Market:](#)

Executive Summary

DelveInsight's 'Nonalcoholic Steatohepatitis (NASH)- Market Insights, Epidemiology and Market Forecast-2027' report provides a disease overview of the Nonalcoholic Steatohepatitis (NASH) along with the epidemiology and the market scenario in the 7MM – United States, EU5 (Germany, France, Spain Italy , United Kingdom) and Japan.

The Report covers the therapeutics market revenue, treatment practice and Nonalcoholic Steatohepatitis (NASH) forecasted market share from 2017 to 2027 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Nonalcoholic Steatohepatitis (NASH) till 2027. Our epidemiology forecast covers the prevalent population as well as the diagnosed population having Nonalcoholic Steatohepatitis (NASH).

The report also covers the detailed market size forecast for 7MM. According to DelveInsight, it is estimated that the market size of Nonalcoholic Steatohepatitis (NASH) in 7MM shall increase and reach up to 49.25 Billion in 2027, with the compound annual growth rate (CAGR) of 23.0% for the period i.e., 2015-2027.

Request Sample Report @ <https://www.wiseguyreports.com/sample-request/2477598-non-alcoholic-steatohepatitis-nash-market-insights-epidemiology-and-market-forecast-2027>

Nonalcoholic Steatohepatitis (NASH) is a subtype of NAFLD (Nonalcoholic Fatty Liver Disease) that is characterized by accumulation of large amount of fat in the liver, along with inflammation and scarring. NASH is one of the most common liver related health problem and is considered to be strongly associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus (T2DM), arterial hypertension, and hypertriglyceridemia. The condition can further progress to cirrhosis, liver failure and rarely liver cancer.

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) market.

Organize sales and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis (NASH) in US, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan.

To understand the future market competition in the global Nonalcoholic Steatohepatitis (NASH) market and Insightful review of the key market drivers and barriers.

To understand the regulatory scenario in major markets.

For further information on this report, visit - <https://www.wiseguyreports.com/enquiry/2477598-nonalcoholic-steatohepatitis-nash-market-insights-epidemiology-and-market-forecast-2027>

Table of Contents

1. Report Introduction
2. Non-Alcoholic Steatohepatitis Market Overview at a Glance
3. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2016
4. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2027
5. Non-Alcoholic Steatohepatitis
 - 5.1. Introduction
 - 5.2. Types
 - 5.3. Classification of NASH: Stages of Fibrosis
 - 5.4. Causes
 - 5.5. Pathophysiology
 - 5.6. Symptoms
 - 5.7. Diagnosis
6. Epidemiology and Patient Population
7. Key Points:
8. Population and Forecast Parameters
9. Prevalent Population of NASH in 7MM
10. Region-Wise Prevalent Population of NASH
11. Diagnosed Population of NASH in 7MM
12. Region-Wise Diagnosed Population of NASH
13. Treatment Algorithm
14. American Association for the Study of Liver Diseases (AASLD) Current Recommendations for NAFLD/NASH
15. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
16. Guideline for NAFLD/NASH, by the Japanese Society of Gastroenterology (JSG) in cooperation with "The Japan Society of Hepatology"

- 17. Unmet Needs
- 18. Emerging Drugs
 - 18.1. Phase-III Drugs Analysis
 - 18.2. Phase-II Drugs Analysis
- 19. Emerging Therapies
 - 19.1. Elafibranor(GFT505): GenfitPharma
 - 19.1.1. Regulatory Milestones
 - 19.1.2. Other development activities
 - 19.1.3. Clinical Development
 - 19.1.4. Ongoing Trials Information
 - 19.1.5. Safety and Efficacy
 - 19.1.6. Advantages and Disadvantages
 - 19.1.7. Product Profile
 - 19.2. Obeticholic Acid (OCA): Intercept Pharmaceuticals, Inc.
 - 19.2.1. Regulatory milestones
 - 19.2.2. Other development activities
 - 19.2.3. Clinical Development
 - 19.2.4. Ongoing Trials Information
 - 19.2.5. Safety and Efficacy
 - 19.2.6. Advantages and Disadvantages
 - 19.2.7. Product Profile
 - 19.3. Selonsertib (Ask-1 Inhibitor): Gilead Sciences, Inc.
 - 19.3.1. Other development activities
 - 19.3.2. Clinical Development
 - 19.3.3. Clinical Pipeline Activity
 - 19.3.4. Safety and Efficacy
 - 19.3.5. Advantages and Disadvantages
 - 19.3.6. Product Profile
 - 19.4. Cenicriviroc (CVC): Allergan/Tobira Therapeutics
 - 19.4.1. Regulatory milestones
 - 19.4.2. Other development activities
 - 19.4.3. Clinical Development
 - 19.4.4. Ongoing Trials Information
 - 19.4.5. Safety and Efficacy
 - 19.4.6. Advantages and Disadvantages
 - 19.4.7. Product Profile
 - 19.5. NGM282: NGM Biopharmacueticals, Inc.
 - 19.5.1. Other development activities
 - 19.5.2. Clinical Development
 - 19.5.3. Ongoing Trials Information
 - 19.5.4. Safety and Efficacy
 - 19.5.5. Advantages and Disadvantages
 - 19.5.6. Product Profile

- 19.6. BMS-986036: Bristol-Myers Squibb Company
 - 19.6.1. Other development activities
 - 19.6.2. Clinical Development
 - 19.6.3. Ongoing trials information
 - 19.6.4. Safety and Efficacy
 - 19.6.5. Advantages and Disadvantages
 - 19.6.6. Product Profile
- 19.7. Emricasan: Conatus Pharmaceuticals Inc.
 - 19.7.1. Regulatory milestones
 - 19.7.2. Other development activities
 - 19.7.3. Clinical Development
 - 19.7.4. Ongoing trials information
 - 19.7.5. Safety and Efficacy
 - 19.7.6. Product Profile
- 19.8. IVA337: Inventiva Pharma
 - 19.8.1. Regulatory milestones
 - 19.8.2. Clinical Development
 - 19.8.3. Ongoing trial information
 - 19.8.4. Safety and Efficacy
 - 19.8.5. Product Profile
- 20. Nonalcoholic Steatohepatitis (NASH): Country-Wise Market Analysis
- 21. United States
- 22. Europe
- 23. Germany
- 24. France
- 25. Italy
- 26. Spain
- 27. United Kingdom
- 28. Japan
- 29. Market Drivers
- 30. Market Barriers
- 31. Appendix
- 32. Report Methodology
- 33. Consulting Services

Continuous...

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2477527

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/414385287>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.